Innovation Pharmaceuticals Inc. (IPIX)
| Market Cap | 85.21M |
| Revenue (ttm) | 23,000 |
| Net Income (ttm) | -6.27M |
| Shares Out | 337.49M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 13 |
| Last Price | $0.1755 |
| Previous Close | $0.1800 |
| Change ($) | -0.0050 |
| Change (%) | -2.50% |
| Day's Open | 0.1725 |
| Day's Range | 0.1710 - 0.1837 |
| Day's Volume | 827,436 |
| 52-Week Range | 0.053 - 0.65 |
News
Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month
WAKEFIELD, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces additional independent ...
About IPIX
Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It develops Brilacidin, a lead drug compound for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. It has license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Ch... [Read more...]
| Industry Biotechnology | |
| CEO Leo Ehrlich | Employees 4 |
| Stock Exchange OTCMKTS | Ticker Symbol IPIX |